First Heartland Consultants Inc. Decreases Stock Position in Pfizer Inc. (NYSE:PFE)

First Heartland Consultants Inc. lessened its stake in Pfizer Inc. (NYSE:PFE) by 2.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,411 shares of the biopharmaceutical company’s stock after selling 375 shares during the quarter. First Heartland Consultants Inc.’s holdings in Pfizer were worth $431,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Olistico Wealth LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer in the second quarter valued at approximately $29,000. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at $32,000. Trivant Custom Portfolio Group LLC boosted its stake in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares in the last quarter. Finally, DiNuzzo Private Wealth Inc. acquired a new position in Pfizer during the fourth quarter worth about $37,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

NYSE PFE traded down $0.02 on Monday, hitting $28.88. 6,217,626 shares of the stock were exchanged, compared to its average volume of 38,807,285. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $36.94. The company has a market capitalization of $163.65 billion, a PE ratio of -483.83, a P/E/G ratio of 0.98 and a beta of 0.69. The business’s fifty day moving average is $28.85 and its 200 day moving average is $27.97. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.67 EPS. Research analysts anticipate that Pfizer Inc. will post 2.68 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.82%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio is presently -2,800.00%.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. UBS Group raised their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Wells Fargo & Company lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, August 19th. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.